291 related articles for article (PubMed ID: 28216214)
1. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
[TBL] [Abstract][Full Text] [Related]
2. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
[TBL] [Abstract][Full Text] [Related]
4. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
[TBL] [Abstract][Full Text] [Related]
6. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842
[TBL] [Abstract][Full Text] [Related]
8. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
9. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
[TBL] [Abstract][Full Text] [Related]
10. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
[TBL] [Abstract][Full Text] [Related]
11. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
[TBL] [Abstract][Full Text] [Related]
12. A multicenter post-marketing evaluation of the Elixir DESolve
Nef H; Wiebe J; Boeder N; Dörr O; Bauer T; Hauptmann KE; Latib A; Colombo A; Fischer D; Rudolph T; Foin N; Richardt G; Hamm C
Catheter Cardiovasc Interv; 2018 Nov; 92(6):1021-1027. PubMed ID: 29508518
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
[TBL] [Abstract][Full Text] [Related]
14. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
[TBL] [Abstract][Full Text] [Related]
15. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
[TBL] [Abstract][Full Text] [Related]
18. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
